Clinical trial NCT00967200: Study of Tissue Samples From Patients With Glioma or Other Brain Tumors
Official title: Identification of Genes Involved in the Pathogenesis of Gliomas by Transcriptome Analysis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Central Nervous System Lymphoma
Keywords: adult anaplastic astrocytoma
adult diffuse astrocytoma
adult glioblastoma
adult giant cell glioblastoma
adult gliosarcoma
adult pilocytic astrocytoma
adult pineal gland astrocytoma
adult subependymal giant cell astrocytoma
adult brain stem glioma
adult choroid plexus tumor
adult craniopharyngioma
adult ependymoblastoma
adult medulloblastoma
adult supratentorial primitive neuroectodermal tumor (PNET)
adult anaplastic ependymoma
adult ependymoma
adult myxopapillary ependymoma
adult subependymoma
meningeal melanocytoma
adult meningeal hemangiopericytoma
adult grade I meningioma
adult grade II meningioma
adult anaplastic meningioma
adult papillary meningioma
adult anaplastic oligodendroglioma
adult oligodendroglioma
adult pineoblastoma
adult pineocytoma
adult mixed glioma
recurrent adult brain tumor
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
First posted: 2009-08-27
Enrollment: 180
Sex: ALL
Minimum age (years): 18
Maximum age (years): 120
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Pathophysiology of gliomas and identification of molecular markers that may predict prognosis and progression or that could identify new therapeutic

Brief summary: RATIONALE: Studying the genes expressed in samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

PURPOSE: This research study is looking at tissue samples from patients with glioma or other brain tumors.

Detailed description: OBJECTIVES:

Primary

* To better understand the pathophysiology of gliomas and identify molecular markers that may predict prognosis and progression or that could identify new therapeutic approaches.

Secondary

* To compare gene expression profiles, in terms of response to treatment, and attempt to isolate subgroups of patients with objective response to certain types of chemotherapy or radiotherapy.

OUTLINE: This is a multicenter study.

Biological samples are collected from patients at time of surgery for diagnostic and/or treatment purposes.

Eligibility criteria: Inclusion Histologically confirmed glioma of any grade or rare primary brain tumor No urgent situation No known or suspected active infection Must not be deprived of liberty or protected by law Not pregnant or nursing

Exclusion :

No concurrent participation in other trials that require a period of exclusion

Primary outcomes:
measure: Pathophysiology of gliomas
timeFrame: 1 day
Secondary outcomes:
measure: Identification of molecular
timeFrame: 1 day
Other outcomes:
Locations:
city: Montpellier
country: France
facility: CHU Montpellier
city: Montpellier
country: France
facility: Clinique Gui de Chauliac
Study officials:
affiliation: University Hospital, Montpellier
name: Luc Bauchet, MD
role: PRINCIPAL_INVESTIGATOR
References: